PDF icon Download PDF
Open Access
CC BY 4.0 · Journal of Health and Allied Sciences NU 2024; 14(01): 038-046
DOI: 10.1055/s-0043-1769903
Review Article

Drug Reprofiling: A Prospective Approach to Battle Chronic Ailments

Natasha Naval Aggarwal 
1   Department of Pharmachemistry, Yenepoya Pharmacy College and Research Center, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
,
S.M. Sindhoor 
2   Department of Pharmaceutics, P.A College of Pharmacy, Nadupadav, Montepadav Post, Kairangala, Mangalore, Karnataka, India
,
N. Raghavendra Naveen
3   Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, Mangaluru
,
Buduru Gowthami
4   Department of Pharmaceutics, Annamacharya College of Pharmacy, New Boyanapalli, Rajampet, Andhra Pradesh, India
,
Prajitha Biju
5   Department of Pharmaceutics, Yenepoya Pharmacy College & research Centre, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
› Author Affiliations
Funding This review did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

The concept of drug “reprofiling” has garnered attention in the recent past post the outbreak of coronavirus disease 2019 when traditional drug discovery seemed to fail. Even though repurposing is called pharma-friendly in terms of monetary relief, clinical trials play an integral role in repurposed nontarget /combination moieties. Nevertheless, when a drug exhibits no returns to the market, an exhaustive study on mechanism of action (MOA) can help for reprofiling of drugs for new indications. However, several papers have claimed that scarcity of resources and data access, and staffing issues, tends to pull down reprofiling of drugs. In contrast to this notion, a total of 155 patented articles to date give a strong base for drug repurposing. In the present review, a scientific prospection of reprofiled antifungal and antiviral agents for the past decade was made using the PubMed database wherein a total of 410 and 768 publications have resulted respectively. The authors have attempted to focus their attention to repurposing antifungal drugs for chronic ailments and infectious diseases by understanding their MOA.

For example, antifungal azoles, which work by blocking ergosterol synthesis, can be repurposed as they inhibit histone deacetylase as well significantly decrease the production of cytokines and modulate the inflammatory pathways used by cancer cells.

Hence, we believe that the mentioned Food and Drug Administration-approved drug candidates can be utilized to treat nontarget diseases, notably rare/neglected diseases as well as chronic illnesses and the more recent viral infections that are spreading globally.

Keywords

antibiotic - FDA-approved - tumors

Statement of Institutional Review Board Approval and/or Statement of Conforming to the Declaration of Helsinki

Not Applicable.


Authors' Contributions

P.B. was involved in hypothesis of the subject and article writing, preparing the final draft Natasha. N.A. was involved in article writing, hypothesis of the subject, and article correction. S.S.M. contributed to hypothesis of the subject and article correction. N.R.N. and B.G. helped in article writing. All authors have read and approved the manuscript.




Publication History

Article published online:
20 June 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India